RxDoctor Payments Data

Chelsea Ching Endow, MD

Internal Medicine · Honolulu, HINPI 1609087832

Payments from drug & device makers

$700in general payments, 2019–2025

Across 36 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$213
  • Kowa Pharmaceuticals America, Inc.$163
  • AbbVie$65
  • Merck$58
  • Astellas Pharma US Inc$46
  • Ironwood Pharmaceuticals, Inc$35
  • plus $121 from 6 others

What the payments were for

  • Consulting fees$17525%
  • Food & beverage$52575%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$700 in reported general payments places this provider in the 65th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$88,644
Medicare patients
168
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis12$264,528
OzempicSemaglutide61$147,768
JardianceEmpagliflozin72$105,350
EliquisApixaban73$101,040
JanuviaSitagliptin Phosphate78$98,216
TrulicityDulaglutide47$88,467
ProliaDenosumab46$79,334
RybelsusSemaglutide17$34,683
JanumetSitagliptin Phos/Metformin Hcl21$32,620
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$29,634
TradjentaLinagliptin24$27,454
Janumet XrSitagliptin Phos/Metformin Hcl19$27,115
XareltoRivaroxaban16$26,601
Combivent RespimatIpratropium/Albuterol Sulfate11$21,840
Atorvastatin Calcium663$18,815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$58$157,951118 claims
Lilly USA, LLCTrulicity$26$88,46747 claims
AmgenProlia$213$79,33446 claims
Johnson & JohnsonXarelto$14$26,60116 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$27$18,20313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →